The WuXi AppTec, Celgene, Taikang and Tigermed-backed cancer drug developer went public in Hong Kong at the top of its range.

TDK Ventures, Paz Oil and Landa Ventures-backed hydrogen and ammonia fuel cell technology developer raised $60.7m in an Israel flotation.

William Hill sold $11.5m shares in the $81.7m initial public offering but remains the lottery software producer's largest shareholder.

Chint, Sinopec, Intel, Wanxiang and Lenovo-backed process automation technology producer Supcon has priced an offering on Shanghai's Star Exchange.

WuXi AppTec and Juno Therapeutics' joint cancer immunotherapy venture has listed on the Hong Kong Stock Exchange.

The AIG, Illumina, Alphabet and Orient Life-backed cell therapy developer priced its shares at the bottom of the range to raise $70.6m.

Ping An's financial services spinoff raised $2.36bn in a US initial public offering that represented an exit for Bank of China, Cofco, SBI and several investment banks.

Novo, Bristol Myers-Squibb and Merck Group scored exits as the fibrosis and cancer drug developer priced its shares in the middle of the IPO's range.

Several corporates are set to exit the financial services provider in the biggest IPO in history, while parent company Alibaba will buy about $7.5bn of shares.

Roche and Novo-backed small molecule therapy developer Aligos Therapeutics has floated in an initial public offering priced in the middle of its range.